General Motors to recall 2.5 million vehicles in China over Takata’s faulty airbag issue
Category: #world  By Saipriya Iyer  Date: 2017-09-20
  • share
  • Twitter
  • Facebook
  • LinkedIn

General Motors to recall 2.5 million vehicles in China over Takata’s faulty airbag issue

General Motors is on the verge of dealing with a major blow in the world’s largest automotive market, China, over concerns about faulty air bag inflators manufactured by Japanese automotive giant, Takata. The U.S. automaker, along with its Chinese joint venture partner, Shanghai GM, is expected to withdraw over 2.5 million cars as an aftermath, cite reliable sources. The companies would be starting their first recall from the end of October, this year, with 13,492 imported Opel and Saab vehicles, followed by another round of withdrawal process involving over 2.51 million Opel and Buick cars that are claimed to begin from December 29, 2017.

The recall comes after a similar kind of withdrawal announcement that made to the headlines last week by Volkswagen and its joint venture in China. The German carmaker along with its joint venture partners has announced to recall approximately 4.86 million cars over Takata’s air bag issue. The vehicles that are claimed to be recalled by General Motors are equipped with hazardous air bag inflators that have the potential to create an explosion and could spray fatal shrapnel inside the car. This is not the first time Takata has been dragged into a controversy. In fact, citing reliable sources, Takata air bags inflators have been closely linked with at least 180 injuries and 16 casualties on a global scale. Undoubtedly, the defect has led to the biggest recall in the history of automotive market.

Reportedly, Takata has till date recalled almost 100 million airbags that the Japanese manufacturer had produced for some of the top notch automotive giants, with U.S. procuring the major chunk of this humongous figure. Estimates claim that U.S. accounted for almost 70 million faulty air bag inflators. As far as China is concerned, the defective airbag case involves almost 37 automotive manufacturers encompassing more than 20 million vehicles, out of which 24 automakers had already recalled 10.59 million cars by June end.

It goes without saying that the China automotive market is crucial for international carmakers. General Motors having a strong presence in the country is an evidence to this fact. Accounting for a sale of around 3.87 million vehicles in 2016, the U.S. automaker is claimed to be the second largest foreign manufacturer in China market, after Volkswagen. In order to maintain its business position and commitment in the market, GM has agreed to replace the defective airbags with new ones free of cost, cite reliable sources.



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Foodics enters Egypt market by setting an on-ground presence in Cairo
Foodics enters Egypt market by setting an on-ground presence in Cairo
By Saipriya Iyer

Saudi Arabia-based restaurant management platform Foodics, has announced that it has entered the Egyptian market by creating an on-the-ground presence in Cairo.  The expansion comes after the company raised USD 4 ...

Food Emulsifiers Market to Witness an Appreciable Growth By 2026
Food Emulsifiers Market to Witness an Appreciable Growth By 2026
By Saipriya Iyer

This advanced report on the Food Emulsifiers Market includes of an in-depth overview of this business sphere. Alongside, details of the present market size and status have been given. The report aims to provide substantial updates on the market, p...

Bharat Biotech reveals positive data from animal trial of Covaxin
Bharat Biotech reveals positive data from animal trial of Covaxin
By Saipriya Iyer

Bharat Biotech, an Indian biotechnology company, has reportedly revealed positive results from the animal trial of Covaxin, India’s COVID-19 vaccine candidate.

In the animal t...